InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,432.17
(
0.01%
)
US TECH 100
19,182.80
(
0.08%
)
Dow Jones
38,531.67
(
-0.15%
)
Brent Oil
82.81
(
0.83%
)
Bitcoin
65,711.32
(
-1.39%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 137

Friday, 05/04/2018 6:33:59 AM

Friday, May 04, 2018 6:33:59 AM

Post# of 438
XLRN has two mid-year Ph3 read-outs:

* Myeloplastic syndrome
* beta-Thalassemia

Lead compound is a first-in-class treatment for rare blood disorders being co-developed with CELG.

5/1/18 received fast track status to treat muscular dystrophy of the face scapula & upper arms

Edward White, a tipranks 5-star analyst from Wainwright recently reiterated a buy.

Cash runway will get XLRN into 2021.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up